Perspectives on variability in pharmacokinetics of an oral contraceptive product

详细信息    查看全文

• 作者：William J. Jusko ; ^{wjjusko@buffalo.edu}
• 关键词：Pharmacokinetics ; Oral contraceptives ; Ethinyl estradiol ; Levonorgestrel
• 刊名：Contraception
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：95
• 期：1
• 页码：5-9
• 全文大小：231 K
• 卷排序：95

文摘

The early literature and reviews have described the pharmacokinetics (PK) of oral contraceptive (OC) compounds such as ethinyl estradiol (EE) and levonorgestrel (LNG) in women as subject to large intersubject variability. This was partly due to the use of diverse radioimmunoassays, limited sampling periods and an incomplete understanding of single- vs. multiple-dose kinetics and the role of EE in causing both inhibition of hepatic metabolism along with induction of sex hormone binding globulin. Over the past two decades, LNG and EE have been used as target drugs for the assessment of possible drug interactions upon introduction of many new therapeutic agents. This has resulted in at least 17 publications that describe the PK of LNG and EE in women using various 150 mcg/30 mcg products under fairly standard multiple-dose conditions. A review of these studies indicates only moderate variability in the Cmax and area under the curve both within and across these studies. There is impressive similarity in these drug exposure indices found in studies carried out with several products by investigators at numerous sites and countries.